National Institute of Mental Health (NIMH): Depression trials

The registry lists 87 Depression studies with National Institute of Mental Health (NIMH) as lead sponsor. 11 are open to participants now and 15 have results posted.

Early Phase 1 1Phase 1 13Phase 2 24Phase 3 3Phase 4 8No phase 41(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ecological Momentary Assessment of State-Dependent Decision-Making and Metacognition Across a Psychopathology ContinuumNot yet recruitingNCT07801079
• Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant DepressionRecruitingNCT06511908Phase 2
• Natural History of Depression, Bipolar Disorder and Suicide RiskRecruitingNCT06462196
• [18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PETRecruitingNCT05703685Phase 1
• Long-term Observation of Participants With Mood DisordersRecruitingNCT04877977
• PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)RecruitingNCT04582916Phase 1
• Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major DepressionRecruitingNCT03973268Phase 1
• Characterization and Treatment of Adolescent DepressionRecruitingNCT03388606
• Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderRecruitingNCT03065335Phase 1
• Neurobiology of SuicideRecruitingNCT02543983Phase 2
• Evaluation of Patients With Mood and Anxiety Disorders and Healthy VolunteersRecruitingNCT00024635
• [11C]-(R)-Rolipram to Measure cAMP Signaling Before and After KetamineTerminatedNCT05522673Phase 1Results posted
• Antidepressant Effects of TS-161 in Treatment-Resistant DepressionTerminatedNCT04821271Phase 2Results posted
• Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)CompletedNCT03861000Phase 1/2Results posted
• Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive DisorderCompletedNCT02484456Phase 2Results posted
• Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?TerminatedNCT02049385Phase 1/2Results posted
• Combining Medications to Enhance Depression OutcomesCompletedNCT00590863Phase 4Results posted
• Antidepressant Effects of NR2B in Major DepressionCompletedNCT00472576Phase 1Results posted
• The Antidepressant Efficacy of the Anticholinergic ScopolamineTerminatedNCT00369915Phase 2Results posted
• Org 24448 to Treat Major DepressionTerminatedNCT00113022Phase 2Results posted
• Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral ContraceptivesTerminatedNCT00089414Phase 2Results posted
• Rapid Antidepressant Effects of Ketamine in Major DepressionCompletedNCT00088699Phase 1/2Results posted
• Lexapro and Pramipexole and to Treat Major DepressionCompletedNCT00086307Phase 2Results posted
• Rapid Antidepressant Effects of Yohimbine in Major DepressionCompletedNCT00078715Phase 2Results posted
• Clinical Trial of Estrogen for Postpartum DepressionTerminatedNCT00059228Phase 2Results posted
• Raloxifene and Rimostil for Perimenopause-Related DepressionCompletedNCT00030147Phase 4Results posted
• Mental Health Impact of the COVID-19 Pandemic on Amish and Mennonite Participants in AMBiGenCompletedNCT04684615
• Brain Inflammation in Major Depressive Disorder BackgroundCompletedNCT01851356
• A Pilot Study to Extend the K-SADS-PL to Adolescents and Young AdultsCompletedNCT01778478
• Brain Imaging, Genetics and Treatment for Major DepressionWithdrawnNCT01568684Phase 1
• Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive DisorderWithdrawnNCT01313403Not applicable
• PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1ACompletedNCT01198197Early Phase 1
• PET Whole Body Distribution Studies Using [11C]CUMICompletedNCT01132872
• Depression Outcomes Study of ExerciseCompletedNCT00964054Phase 1
• p11 Protein Levels in Patients With Major Depressive Disorder Treated With CitalopramCompletedNCT00697268
• Assessing Treatment Emergent Suicidal Ideation in Patients With Major DepressionCompletedNCT00532103
• Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant MedicationCompletedNCT00375843Phase 4
• Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed PatientsCompletedNCT00369798Phase 1
• Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar DisorderWithdrawnNCT00327756Phase 2
• Parent Psychoeducation and Cognitive Behavior Therapy for Latino Adolescents With DepressionStatus unknownNCT00118469Phase 2
• Dopamine Receptor Imaging in Mood DisordersCompletedNCT00116077
• Hormonal Causes of Menstrual-Related Mood DisordersCompletedNCT00100360
• Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood DisordersCompletedNCT00097175
• Neurocardiac Control in Major DepressionCompletedNCT00084162
• Dutasteride to Treat Women With Menstrually Related Mood DisordersCompletedNCT00082043Phase 1
• Function of Catecholamines in the Brain During DepressionCompletedNCT00082030
• FMRI Study of Performance During a Probabilistic Reversal Learning Task in DepressionCompletedNCT00075296
• Evaluating Brain Responses to Facial Expressions in Major Depressive DisorderCompletedNCT00071123
• An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant DepressionCompletedNCT00070694Phase 2
• The Psychobiology of Childhood TemperamentCompletedNCT00060775
• The Effects of Estrogen Withdrawal on Mood Symptoms in WomenCompletedNCT00060736
• Brain Regulation of Emotions in People With Depression and AnhedoniaCompletedNCT00059579
• Screening Evaluation for Women With Postpartum DepressionTerminatedNCT00056901
• Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging StudiesTerminatedNCT00055575Phase 2
• Brain Imaging in DepressionCompletedNCT00050700
• MRI Study of Brain Activity and Risk for Depression in AdolescentsCompletedNCT00047944
• Ethnic Variations in Antidepressant ResponseCompletedNCT00047671Phase 4
• Examination of a Soy-Based Supplement for Major DepressionCompletedNCT00042380Phase 2
• Clinical Trial of Memantine for Major DepressionCompletedNCT00040261Phase 3
• Clinical Trial of Felbamate for Treatment-Resistant Bipolar DepressionCompletedNCT00034229Phase 2
• Serotonin Function During DepressionCompletedNCT00033787
• Evaluation of Clonazepam and Paroxetine for Panic Disorder With DepressionCompletedNCT00031317Phase 4
• The Treatment of Children and Adolescents With Treatment-Resistant DepressionCompletedNCT00029640
• Reward-Related Processes and Brain FunctionCompletedNCT00029588
• Examination of Brain Serotonin Receptors in Patients With Mood DisordersCompletedNCT00026832
• Riluzole to Treat Major DepressionCompletedNCT00026052Phase 2
• Sequenced Treatment Alternatives to Relieve Depression (STAR*D)CompletedNCT00021528Phase 4
• Treatment for Adolescents With Depression Study (TADS)CompletedNCT00006286Phase 3
• Bone Loss in Premenopausal Women With DepressionCompletedNCT00006180Phase 4
• Treatment of Depression in Youth With Bipolar DisordersTerminatedNCT00005015Phase 3
• Treatment of Major Depression With St. John's Wort (Hypericum)CompletedNCT00005013Not applicable
• Combined Hormone Replacement in Menstrually-Related Mood DisordersCompletedNCT00005011
• Heart Disease Risk Factors in Major DepressionCompletedNCT00001969
• Use of Bone Biopsy to Better Understand the Causes of Decreased Bone Mineral Density in DepressionCompletedNCT00001916
• Evaluation of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Mood DisordersCompletedNCT00001545Phase 2
• Dynamics of Leptin and Endocrine FunctionCompletedNCT00001543
• Treatment of Mid-Life-Related Mood DisordersCompletedNCT00001487Phase 2
• Acute Effectiveness of Additional Drugs to the Standard Treatment of DepressionCompletedNCT00001483Phase 2
• Glucocorticoid Effects on Cellular Cytokine ReleaseCompletedNCT00001415
• Bone Mineral Density in Women With Major DepressionCompletedNCT00001413
• Effects of Sex Hormones on Circadian Rhythm in Men and WomenCompletedNCT00001285
• Brain Tissue Collection for Neuropathological StudiesTerminatedNCT00001260
• Perimenopause-Related Mood and Behavioral DisordersCompletedNCT00001231
• Evaluation of the Genetics of Bipolar DisorderCompletedNCT00001174
• Study of the Psychological Development of Children of Parents With and Without Affective DisordersCompletedNCT00001170
• Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled TrialCompletedNCT00001146Phase 2
• Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive DisorderCompletedNCT00000375Phase 4